Trimetrexate

Trimetrexate

Clinical data
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a694019
ATC code	P01AX07 (WHO)
Pharmacokinetic data
Bioavailability	VD: 20-30 Liters
Metabolism	Oxidative O-demethylation, followed by conjugation with glucuronide or sulfate
Biological half-life	11 to 12 hours
Identifiers
IUPAC name 5-methyl-6-[(3,4,5-trimethoxyphenyl) aminomethyl] quinazoline-2,4-diamine
CAS Number	52128-35-5 Y
PubChem (CID)	5583
IUPHAR/BPS	7613
DrugBank	DB01157 Y
ChemSpider	5381 Y
UNII	UPN4ITI8T4 Y
KEGG	D06238 Y
ChEMBL	CHEMBL119 Y
Chemical and physical data
Formula	C19H23N5O3
Molar mass	369.418 g/mol
3D model (Jmol)	Interactive image
SMILES n3c1c(c(c(cc1)CNc2cc(OC)c(OC)c(OC)c2)C)c(nc3N)N
InChI InChI=1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24) Y Key:NOYPYLRCIDNJJB-UHFFFAOYSA-N Y

Trimetrexate is a quinazoline derivative. It is a dihydrofolate reductase inhibitor.

It has been used with leucovorin in treating pneumocystis pneumonia.

It has been investigated for use in treating leiomyosarcoma. It is a methotrexate (MTX) analog that is active against transport-deficient MTX-resistant tumor cells that overcome the acquired and natural resistance to methotrexate. Other uses include skin lymphoma.